Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 19 07 2019
revised: 08 12 2019
accepted: 01 02 2020
pubmed: 12 2 2020
medline: 28 4 2021
entrez: 12 2 2020
Statut: ppublish

Résumé

Central venous access devices (CVAD) are commonly employed in the management of cancer patients. While having several benefits they are associated with significant risks. To review the incidence and risk factors for catheter-related thrombosis (CRT) in cancer patients with a CVAD. We performed a prospective observational cohort study of adult patients with cancer requiring a CVAD between 1 January 2004 and 29 June 2016. The rate of, and risk factors for the development of, symptomatic CRT were evaluated. A total of 4920 central lines was inserted into 3130 patients. The incidence of CRT was 3.6%. CRT developed a median of 12 days following line insertion. Peripherally inserted central catheters (PICC) were associated with the highest rates of CRT (hazards ratio (HR) 22.2, 95% confidence interval (CI) 2.9-170.6). Older age groups developed CRT at lower rates (HR 0.57; 95% CI 0.39-0.84 for age 50-61 years, and HR 0.63; 95% CI 0.45-0.89 for age >61 years) compared to age <50 years. Increased CRT was seen in patients with prior CRT (HR 1.81; 95% CI 1.19-2.77). There was a trend to more CRT events with a Khorana tumour score of 1 compared to those with a score of 0 (HR 1.37, 95% CI 1.00-1.88). Hodgkin lymphoma, germ cell and oesophagus cancers had the highest CRT rates. Side of insertion was not associated with thrombosis risk (HR 0.77; 95% CI 0.57-1.05; P = 0.10). Age <50 years, PICC lines and prior CRT were associated with highest CRT rate. Cancer subtype and insertion side were not predictive of thrombosis.

Sections du résumé

BACKGROUND BACKGROUND
Central venous access devices (CVAD) are commonly employed in the management of cancer patients. While having several benefits they are associated with significant risks.
AIM OBJECTIVE
To review the incidence and risk factors for catheter-related thrombosis (CRT) in cancer patients with a CVAD.
METHODS METHODS
We performed a prospective observational cohort study of adult patients with cancer requiring a CVAD between 1 January 2004 and 29 June 2016. The rate of, and risk factors for the development of, symptomatic CRT were evaluated.
RESULTS RESULTS
A total of 4920 central lines was inserted into 3130 patients. The incidence of CRT was 3.6%. CRT developed a median of 12 days following line insertion. Peripherally inserted central catheters (PICC) were associated with the highest rates of CRT (hazards ratio (HR) 22.2, 95% confidence interval (CI) 2.9-170.6). Older age groups developed CRT at lower rates (HR 0.57; 95% CI 0.39-0.84 for age 50-61 years, and HR 0.63; 95% CI 0.45-0.89 for age >61 years) compared to age <50 years. Increased CRT was seen in patients with prior CRT (HR 1.81; 95% CI 1.19-2.77). There was a trend to more CRT events with a Khorana tumour score of 1 compared to those with a score of 0 (HR 1.37, 95% CI 1.00-1.88). Hodgkin lymphoma, germ cell and oesophagus cancers had the highest CRT rates. Side of insertion was not associated with thrombosis risk (HR 0.77; 95% CI 0.57-1.05; P = 0.10).
CONCLUSIONS CONCLUSIONS
Age <50 years, PICC lines and prior CRT were associated with highest CRT rate. Cancer subtype and insertion side were not predictive of thrombosis.

Identifiants

pubmed: 32043739
doi: 10.1111/imj.14780
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1475-1482

Informations de copyright

© 2020 Royal Australasian College of Physicians.

Références

Gonzalez G, Davidoff AM, Howard SC, Pui CH, Rao BN, Shenep JL et al. Safety of central venous catheter placement at diagnosis of acute lymphoblastic leukemia in children. Pediatr Blood Cancer 2012; 58: 498-502.
Chopra V, Ratz D, Kuhn L, Lopus T, Lee A, Krein S. Peripherally inserted central catheter-related deep vein thrombosis: contemporary patterns and predictors. J Thromb Haemost 2014; 12: 847-54.
Cheong K, Perry D, Karapetis C, Koczwara B. High rates of complications associated with peripherally inserted central venous catheters in patients with solid tumours. Intern Med J 2004; 34: 234-8.
Sriskandarajah P, Webb K, Chisholm D, Raobaikady R, Davis K, Pepper N et al. Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients. Thromb J 2015; 13: 21.
Chopra V, Anand S, Hickner A, Buist M, Rogers MA, Saint S et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet 2013; 382: 311-25.
Abdullah JJ, Mohammad N, Sangkar JV, Aziz YFA, Gan GG, Goh KY et al. Incidence of upper limb venous thrombosis associated with peripherally inserted central catheters (PICC). Br J Radiol 2005; 78: 596-600.
Luciani A, Clement O, Halimi P, Goudot D, Portier F, Bassot V et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220: 655-60.
Saber W, Moua T, Williams EC, Verso M, Agnelli G, Couban S et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost 2011; 9: 312-9.
Prandoni P. Peripherally inserted catheters: all that glitters is not gold. Lancet 2013; 382: 288-90.
Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108: 1042-8.
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-7.
Dutia M, White RH, Wun T. Risk assessment models for cancer-associated venous thromboembolism. Cancer 2012; 118: 3468-76.
Mollee P, Jones M, Stackelroth J, van Kuilenburg R, Joubert W, Faoagali J et al. Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. J Hosp Infect 2011; 78: 26-30.
Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013; 11: 71-80.
Craft PS, May J, Dorigo A, Hoy C, Plant A. Hickman catheters: left-sided insertion, male gender, and obesity are associated with an increased risk of complications. Aust N Z J Med 1996; 26: 33-9.
Cadman A, Lawrance JAL, Fitzsimmons L, Spencer-Shaw A, Swindell R. To clot or not to clot? That is the question in central venous catheters. Clin Radiol 2004; 59: 149-355.
Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665-75.
Sperry BW, Roskos M, Oskoui R. The effect of laterality on venous thromboembolism. J Vasc Access 2012; 13: 91.
Lobo BL, Vaidean G, Broyles J, Reaves AB, Shorr RI. Risk of venous thromboembolism in hospitalized patients with peripherally inserted central catheters. J Hosp Med 2009; 4: 417-22.
Chaudhary A, Balakrishnan A, Thai C, Holmstrom B, Nanjappa S, Zhenjun M et al. Validation of the Khorana score in a large cohort of cancer patients with venous thromboembolism. Blood 2016; 128: 879.
Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinsa EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost 2016; 14: 1773-8.
Solari L, Kronig M, Ihorst G, Drognitz K, Heinz J, Jilg CA et al. High rates of thromboembolic events in patients with germ cell cancer undergoing cisplatin-based polychemotherapy. Urol Int 2016; 96: 399-405.
Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012; 9: e1001275.
Leung A, Heal C, Perera M, Pretorius C. A systematic review of patient-related risk factors for catheter-related thrombosis. J Thromb Thrombolysis 2015; 40: 363-73.
Lee AY, Kamphuisen PW. Epidemiology and prevention of catheter-related thrombosis in patients with cancer. J Thromb Haemost 2012; 10: 1491-9.

Auteurs

Marc L Ellis (ML)

Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
School of Medicine, University of Queensland, Brisbane, Queensland, Australia.

Satomi Okano (S)

School of Public Health, University of Queensland, Brisbane, Queensland, Australia.

Andrew McCann (A)

Department of Vascular Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Angela McDowall (A)

Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Rosita Van Kuilenburg (R)

Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Alexandra L McCarthy (AL)

Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Warren Joubert (W)

Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

John Harper (J)

Department of Interventional Radiology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Mark Jones (M)

School of Public Health, University of Queensland, Brisbane, Queensland, Australia.

Peter Mollee (P)

Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
School of Medicine, University of Queensland, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH